Valve-in-valve transfemoral TAVR: Sapien 3 valve within a failed core valve bioprosthesis.
نویسندگان
چکیده
ation in high-risk patients. N Engl J Med 2012;366:1705–1715. 21. Leon MB, Piazza N, Nikolsky E, Blackstone EH, Cutlip DE, Kappetein AP, Krucoff MW, Mack M, Mehran R, Miller C, Morel MA, Petersen J, Popma JJ, Takkenberg JJ, Vahanian A, van Es GA, Vranckx P, Webb JG, Windecker S, Serruys PW. Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. J Am Coll Cardiol 2011;57:253–269. 22. Schroeter T, Linke A, Haensig M, Merk DR, Borger MA, Mohr FW, Schuler G. Predictors of permanent pacemaker implantation after Medtronic CoreValve bioprosthesis implantation. Europace 2012;14:1759–1763. 23. Zoghbi WA, Chambers JB, Dumesnil JG, Foster E, Gottdiener JS, Grayburn PA, Khandheria BK, Levine RA, Marx GR, Miller FA Jr, Nakatani S, Quiñones MA, Rakowski H, Rodriguez LL, Swaminathan M, Waggoner AD, Weissman NJ, Zabalgoitia M. Recommendations for evaluation of prosthetic valves with echocardiography and Doppler ultrasound: a report From the American Society of Echocardiography’s Guidelines and Standards Committee and the Task Force on Prosthetic Valves, developed in conjunction with the American College of Cardiology Cardiovascular Imaging Committee, Cardiac Imaging Committee of the American Heart Association, the European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography and the Canadian Society of Echocardiography, endorsed by the American College of Cardiology Foundation, American Heart Association, European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography, and Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2009;22:975–1014. 24. Tchetche D, Modine T, Farah B, Vahdat O, Sudre A, Koussa M, Lereun C, Nejjari M, Choby M, Rosencher J, Sorbets E, Fajadet J. Update on the need for a permanent pacemaker after transcatheter aortic valve implantation using the CoreValvew AccutrakTM system. EuroIntervention 2012;8:556–562.
منابع مشابه
Noninvasive pacing during transfemoral implantation of the Edwards SAPIEN valve for tricuspid valve bioprosthesis stenosis
Introduction Transcatheter implantation of balloon expandable valves in high-risk patients with degenerated tricuspid bioprostheses has been reported since 2010 [1, 2]. Although there have been cases where the SAPIEN valve was implanted in the tricuspid position without rapid pacing [3, 4], invasive rapid ventricular pacing is usually applied during valve deployment. We present a case report do...
متن کاملTranscatheter Aortic Valve Replacement: A Review Article
Transcatheter aortic valve replacement (TAVR) is a novel therapeutic intervention for the replacement of severely stenotic aortic valves in high-risk patients for standard surgical procedures. Since the initial PARTNER trial results, use of TAVR has been on the rise each year. New delivery methods and different valves have been developed and modified in order to promote the minimally invasive p...
متن کاملValvular Heart Disease Thirty-Day Results of the SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry A European Registry of Transcatheter Aortic Valve Implantation Using the Edwards SAPIEN Valve
Background—Transcatheter aortic valve implantation was developed to mitigate the mortality and morbidity associated with high-risk traditional aortic valve replacement. The Edwards SAPIEN valve was approved for transcatheter aortic valve implantation transfemoral delivery in the European Union in November 2007 and for transapical delivery in January 2008. Methods and Results—The SAPIEN Aortic B...
متن کاملTransfemoral aortic valve replacement with the Edwards SAPIEN and Edwards SAPIEN XT prosthesis using exclusively local anesthesia and fluoroscopic guidance: feasibility and 30-day outcomes.
OBJECTIVES The authors report the feasibility and 30-day outcomes of transfemoral aortic valve replacement (TAVR), using the Edwards SAPIEN (Edwards Lifesciences, Irvine, California) and Edwards SAPIEN XT (Edwards Lifesciences) prosthesis, implanted using exclusively local anesthesia and fluoroscopic guidance. BACKGROUND Transfemoral TAVR is often managed with general anesthesia. However, a s...
متن کاملNeo Left Main Channel Creation Using Double Stenting Alongside a Sapien 3 Aortic Valve Bioprosthesis for Left Main Coronary Obstruction Following Valve-in-Valve Transcatheter Aortic Valve Replacement: A Case Report With Review of Literature
Transcatheter aortic valve replacement in the setting of failed surgical bioprosthesis (valve-in-valve) is a valuable option for patients with bioprosthetic aortic stenosis or regurgitation who are deemed high risk for repeat open heart surgery. Although the procedure is successful with proper preprocedural assessment, instances of left main (LM) coronary artery ostium obstruction have been doc...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- European heart journal
دوره 35 38 شماره
صفحات -
تاریخ انتشار 2014